ATPS-94THIRD GENERATION mTOR INHIBITORS IN GLIOBLASTOMA

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

mTOR inhibitors in sarcoma.

GD Over the last decade, pathology and diagnostics have assumed a new importance in sarcoma. In the past, the belief was that all sarcomas were alike: some were bone sarcomas and some were soft-tissue sarcomas, but it did not matter because the only treatment available if surgery and radiotherapy failed was chemotherapy, and this was only rarely directed at specific subtypes of sarcomas. Some s...

متن کامل

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.

The mTOR signaling pathway is dysregulated in ∼50% of all human malignancies and is a major cancer drug target. Although rapamycin analogs (rapalogs) have shown clinical efficacy in a subset of cancers, they do not fully exploit the antitumor potential of mTOR targeting. Because the mTOR kinase domain is important for rapamycin-sensitive and -insensitive functions, mTOR catalytic inhibitors hav...

متن کامل

Proteasome inhibitors in glioblastoma

[This retracts the article DOI: 10.3892/ol.2017.5585.].

متن کامل

MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Glioblastoma (GBM) represents a compelling disease for kinase inhibitor therapy because most of these tumors harbor genetic alterations that result in aberrant activation of growth factor-signaling pathways. The PI3K/mammalian target of the rapamycin (mTOR) pathway is dysregulated in over 50% of human GBM but remains a challenging clinical target. Inhibitors against PI3K/mTOR mediators have lim...

متن کامل

mTOR inhibitors in cancer therapy

The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Neuro-Oncology

سال: 2015

ISSN: 1522-8517,1523-5866

DOI: 10.1093/neuonc/nov204.94